Clinical Trials: TACT > TACT Home

Recently diagnosed with prostate cancer? You are not alone. 1 in 7 men1 are diagnosed with prostate cancer during their lifetime.

“Traditional prostate cancer treatments – surgery and radiation therapy – provide good local control of the disease, but can leave men with significant long-term complications affecting urinary, bowel and sexual function. These issues can significantly reduce a patient’s quality of life.”

James Relle, M.D., Urologist and Co-principal Investigator of the TULSA-PRO® Ablation Clinical Trial at Beaumont Health. Publication by Beaumont Hospital.

The TULSA-PRO® procedure is intended to ablate prostate tissue using ultrasound thermal energy under guidance by real-time MRI. This is a minimally invasive procedure with short procedure time that will destroy prostate tissue in one session.

TULSA-PRO® Ablation Clinical Trial (TACT) is a clinical study of 110 male patients, between 45 and 80 years old, with biopsy confirmed, localized prostate cancer that is confined to their prostate gland.

TACT is a Pivotal Trial conducted at leading research institutions across the United States, Canada and Europe. Well-known experts in prostate cancer  are participating as the Principle Investigators in this study and are currently recruiting patients. It’s not too late to participate. Ask your doctor if participating in TULSA-PRO® TACT trial is right for you.  Locate a Trial Site Near You

For full trial details and eligibility criteria, visit ( identifier NCT02766543 )

1 American Cancer Society

“Unmet need” in current prostate cancer treatments

Dr.Laurence Klotz, Urologist & Professor of surgery